Compare iShares Global Clean Energy ETF (ICLN) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Moderna, Inc. — how do they compare? iShares Global Clean Energy ETF trades at $18.59, while Moderna, Inc. trades at $59.72 (market cap $23.60B). The key difference: Moderna, Inc. is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ICLN | MRNA | |
|---|---|---|
52-Week High | $23.75 | $81.80 |
52-Week Low | $13.41 | $22.36 |
Market Cap | — | $23.60B |
Sector | — | Health |
Enterprise Value | — | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, is trading at $18.14, down 1.25% on the day, with a bearish technical outlook. The ETF provides exposure to 105 global renewable energy companies but lacks key valuation metrics like P/E and P/S ratios. Recent news highlights strong 2026 performance with over 25% gains, driven by AI-related power demand and global energy security concerns.
The outlook for ICLN is mixed, balancing strong sector tailwinds against policy risks. Investment opportunities include exposure to the growing clean energy transition, while risks involve US permit delays threatening $121 billion in projects and ongoing comparisons showing higher-yielding alternatives. The technical picture suggests near-term pressure with key support at $18.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
